Linked Life Data

9256886

Source:http://linkedlifedata.com/resource/pubmed/id/9256886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1997-9-4
pubmed:abstractText
Forty patients with advanced carcinoma of the cervix were prospectively treated by an intermodality approach using chemotherapy combination concomitant with split-course hyperfractionated radiation therapy (RT). Cisplatin (CDDP) (60 mg/m2) was administered before radiotherapy initiation followed by 5-fluorouracil (5-FU) (750 mg/m2) for 5 days during the first week of irradiation. The same schedule was repeated in the last week of the RT, with 5-FU administration (1,000 mg/m2) for only 3 days. RT consisted of 5,020 cGy to the pelvis, followed by two intracavitary applications for a total of 5,000-5,500 mg/h radium equivalent when possible: 140 cGy/fraction was administered in the morning and evening, with a 6-h interval. The remainder of the external beam radiation was delivered at a standard daily fractionation of 180 cGy/fraction to a total dose of 5,020 cGy. This regimen of RT with concomitant chemotherapy had minimal toxicity and did not cause significant prolongation of the treatment program. However, a high rate of late complications was noted in patients who had extended-field RT due to paraaortic lymph node involvement. Thirty-two patients had complete response (CR) (80%). 24 (75%) of whom have no evidence disease (NED), with a median follow-up of 24 months. Our study suggests that this regimen of combined chemotherapy and RT in this group of patients with poor prognosis is effective and well tolerated, with acceptable acute toxicity and late morbidity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0277-3732
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
342-7
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:9256886-Adult, pubmed-meshheading:9256886-Aged, pubmed-meshheading:9256886-Aged, 80 and over, pubmed-meshheading:9256886-Antimetabolites, Antineoplastic, pubmed-meshheading:9256886-Antineoplastic Agents, pubmed-meshheading:9256886-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9256886-Brachytherapy, pubmed-meshheading:9256886-Carcinoma, Squamous Cell, pubmed-meshheading:9256886-Cesium Radioisotopes, pubmed-meshheading:9256886-Cisplatin, pubmed-meshheading:9256886-Clinical Protocols, pubmed-meshheading:9256886-Combined Modality Therapy, pubmed-meshheading:9256886-Disease-Free Survival, pubmed-meshheading:9256886-Female, pubmed-meshheading:9256886-Fluorouracil, pubmed-meshheading:9256886-Follow-Up Studies, pubmed-meshheading:9256886-Humans, pubmed-meshheading:9256886-Lymphatic Metastasis, pubmed-meshheading:9256886-Middle Aged, pubmed-meshheading:9256886-Prognosis, pubmed-meshheading:9256886-Radiopharmaceuticals, pubmed-meshheading:9256886-Radiotherapy Dosage, pubmed-meshheading:9256886-Radium, pubmed-meshheading:9256886-Remission Induction, pubmed-meshheading:9256886-Treatment Outcome, pubmed-meshheading:9256886-Uterine Cervical Neoplasms
pubmed:year
1997
pubmed:articleTitle
Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix.
pubmed:affiliation
Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II, Clinical Trial, Phase I